CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.

We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16,628 de novo acute leukemia patients after allogeneic stem cell transplantation (allo-SCT). Compared with CMV-seronegative recipients who underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of the donor and/or the recipient showed a significantly decreased 2-year leukemia-free survival (44% vs 49%, P < .001) and overall survival (50% vs 56%, P < .001), and increased nonrelapse mortality (23% vs 20%, P < .001). Both groups showed a comparable relapse incidence and 2-year probability of graft-versus-host disease. The negative prognostic effects of CMV seropositivity of the donor and/or the recipient (vs CMV seronegativity of both) were significantly stronger for acute lymphoblastic leukemia (ALL) than for acute myeloid leukemia (AML), resulting in a markedly reduced 2-year overall survival (46% vs 55% for ALL compared with 52% vs 56% for AML). The important prognostic impact of donor/recipient CMV serostatus remained in a multivariate Cox regression analysis including the other prognostic variables. We conclude that donor and/or recipient CMV seropositivity is still associated with an adverse prognosis in de novo acute leukemia patients after allo-SCT despite the implementation of sophisticated strategies for prophylaxis, monitoring, and (preemptive) treatment of CMV.

[1]  S. Forman,et al.  Hematopoietic Cell Transplantation , 2015 .

[2]  B. Sandmaier,et al.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. , 2013, Blood.

[3]  I. Kerridge,et al.  A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low‐, intermediate‐, and high‐risk groups: reactivation risk is increased by graft‐versus‐host disease only in the intermediate‐risk group , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[4]  L. Lanier,et al.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.

[5]  A. Barrett.  CMV: when bad viruses turn good. , 2011, Blood.

[6]  S. Schnittger,et al.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. , 2011, Blood.

[7]  I. Kerridge,et al.  Pre‐transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  E. Thiel,et al.  Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion , 2010, International journal of hematology.

[9]  Irmtraut Koop,et al.  4.23 Graft-versus-Host-Disease , 2009 .

[10]  R. Écochard,et al.  Proportion of long‐term event‐free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program , 2007, Cancer.

[11]  C. Bloomfield,et al.  Cytogenetics in acute leukemia. , 2004, Blood reviews.

[12]  H. Einsele,et al.  Clinical aspects of CMV infection after stem cell transplantation. , 2004, Human immunology.

[13]  Michael Boeckh,et al.  The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. , 2004, Blood.

[14]  H. Einsele,et al.  Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. , 2003, Blood.

[15]  Y. Kodera,et al.  Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation , 2003, Bone Marrow Transplantation.

[16]  M. Boeckh,et al.  Immunosuppressive effects of beta-herpesviruses. , 2003, Herpes : the journal of the IHMF.

[17]  W. Leisenring,et al.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.

[18]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[19]  M. Boeckh,et al.  High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. , 2002, The Journal of infectious diseases.

[20]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[21]  A. Zander,et al.  Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin , 2001, British journal of haematology.

[22]  B. Löwenberg,et al.  Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.

[23]  V. Kuenen-Boumeester,et al.  Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.

[24]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[25]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[26]  D.,et al.  Regression Models and Life-Tables , 2022 .